Q1 Earnings Estimate for VERA Issued By HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Monday, May 5th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.77) EPS.

VERA has been the topic of several other research reports. Wolfe Research started coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 price target on the stock. The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $58.00 target price for the company. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. Finally, Guggenheim upped their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $65.70.

Vera Therapeutics Stock Down 13.8 %

VERA stock opened at $22.01 on Wednesday. The business’s 50-day moving average price is $24.63 and its 200-day moving average price is $35.06. The stock has a market cap of $1.40 billion, a P/E ratio of -8.43 and a beta of 1.28. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same quarter in the prior year, the firm posted ($0.56) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VERA. Avoro Capital Advisors LLC raised its stake in Vera Therapeutics by 30.2% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock valued at $237,247,000 after purchasing an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company’s stock valued at $185,107,000 after buying an additional 437,940 shares in the last quarter. FMR LLC raised its position in shares of Vera Therapeutics by 9.6% during the 4th quarter. FMR LLC now owns 3,053,126 shares of the company’s stock valued at $129,117,000 after buying an additional 267,842 shares in the last quarter. Vanguard Group Inc. grew its position in Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after acquiring an additional 369,387 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP increased its stake in Vera Therapeutics by 31.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company’s stock worth $60,785,000 after acquiring an additional 340,488 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.